A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Trial Profile

A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Erlotinib; Sorafenib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2009 Planned end date changed from 1 Dec 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 02 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top